- Project 4 A prominent feature of castration resistant prostate cancer (CRPC) is an altered lipid environment. Oncogenic changes in androgen receptor- (AR)-dependent transcription dramatically upregulate lipid, sterol, and cholesterol metabolism. Hypercholesterolemia promotes prostate tumor growth, upregulates the steroidogenic enzyme CYP17, increases intratumoral but not circulating androgen, and activates oncogenic signaling pathways. Aggressive PC cells sequester cholesterol by a variety of mechanisms, including upregulation of lipid synthesis, enhanced lipoprotein uptake and down-regulation of sterol export. Epidemiological evidence has linked use of cholesterol-lowering drugs, particularly HMG-CoA reductase inhibitors (statins), with reduced risk of CRPC. In collaboration with Project 1: Chung, we demonstrated for the first time that high circulating cholesterol, with energy intake held constant, promotes metastasis to bone in cooperation with activated RANK. Recently, our lab was the first to report that the chromatin protein, scaffold attachment factor B1 (SAFB1), can act as an AR co-repressor at androgen-responsive genes. SAFB1 is genomically inactivated at high frequency in CRPC and exhibits other characteristics of a tumor suppressor. SAFB1 forms a complex with the histone methyltransferase EZH2, a PC oncoprotein, and with the AR to regulate gene expression by a mechanism involving histone modification. SAFB1 knockdown in PC cells perturbs a transcriptional network of ~900 genes and results in an aggressive phenotype, including resistance to androgen withdrawal. Analysis of this SAFB1-loss network indicates broad effects on sterol/lipid metabolism and chromatin modification. Most of these perturbed genes appear to be distinct from AR- and EZH2-dependent pathways and thus may be largely unstudied in PC. The SAFB1-loss network also converges on androgen metabolism genes in the RANK-mediated network under study in Project 1. There is currently little understanding of how epigenomic alterations seen in PC contribute to the enhanced cholesterol and steroidogenic tumor cell phenotype that emerges in late-stage disease, or how this phenotype might be therapeutically targeted. Based on these novel findings, we will test the hypothesis that SAFB1 loss activates a novel transcriptional program that alters lipid metabolism in a manner that elevates intratumoral cholesterol and androgenic sterols, and enhances intracrine pathways of AR activation. The physiologic significance of SAFB1 loss will be tested within the P01 using 3D culture systems (with Project 2: Farach-Carson), xenografts (with Project 1) and a large series of treatment nave metastatic cases (Project 3:Bhowmick).
The specific aims are:
Aim 1. Test the hypothesis that the chromatin scaffold SAFB1 regulates AR/EZH2- dependent and AR/EZH2-independent transcriptional programs that drive PC metastasis.
Aim 2. Test the hypothesis that SAFB1 loss alters lipid metabolism, intracrine androgen signaling and cooperates with RANKL- dependent mechanisms to promote PC metastasis.

Public Health Relevance

- Project 4 This project centers on determining the role of a DNA-binding protein, SAFB1, in prostate cancer. Loss of SAFB1 function, which occurs in castration-resistant prostate cancer, may promote disease progression and resistance to hormone therapy. We will test the hypothesis that SAFB1 loss appears to be a critical event in progression to advanced disease and that SAFB1 silencing represents a novel therapeutic target.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cedars-Sinai Medical Center
Los Angeles
United States
Zip Code
Rohena-Rivera, Krizia; Bhowmick, Neil A (2018) Notch inhibitor screening reveals an unexpected HES1 heterodimer. J Biol Chem 293:8295-8296
Tighiouart, Mourad; Cook-Wiens, Galen; Rogatko, André (2018) A Bayesian adaptive design for cancer phase I trials using a flexible range of doses. J Biopharm Stat 28:562-574
Madhav, Anisha; Andres, Allen; Duong, Frank et al. (2018) Antagonizing CD105 enhances radiation sensitivity in prostate cancer. Oncogene 37:4385-4397
Jan, Yu Jen; Chen, Jie-Fu; Zhu, Yazhen et al. (2018) NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells. Adv Drug Deliv Rev 125:78-93
Grindel, Brian J; Martinez, Jerahme R; Tellman, Tristen V et al. (2018) Matrilysin/MMP-7 Cleavage of Perlecan/HSPG2 Complexed with Semaphorin 3A Supports FAK-Mediated Stromal Invasion by Prostate Cancer Cells. Sci Rep 8:7262
Jimenez, Jose L; Tighiouart, Mourad; Gasparini, Mauro (2018) Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents. Biom J :
Martinez, Jerahme R; Grindel, Brian J; Hubka, Kelsea M et al. (2018) Perlecan/HSPG2: Signaling role of domain IV in chondrocyte clustering with implications for Schwartz-Jampel Syndrome. J Cell Biochem :
Farach-Carson, Mary C; Lin, Sue-Hwa; Nalty, Theresa et al. (2017) Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow? Front Oncol 7:163
Stewart, Paul A; Khamis, Zahraa I; Zhau, Haiyen E et al. (2017) Upregulation of minichromosome maintenance complex component 3 during epithelial-to-mesenchymal transition in human prostate cancer. Oncotarget 8:39209-39217
Nandana, Srinivas; Tripathi, Manisha; Duan, Peng et al. (2017) Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis. Cancer Res 77:1331-1344

Showing the most recent 10 out of 215 publications